Cargando…
Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma
Metastatic melanoma is a highly immunogenic tumor with very poor survival rates due to immune system escape-mechanisms. Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and the programmed death-1 (PD1) receptors, are being used to impede immune ev...
Autores principales: | Morante, Marta, Pandiella, Atanasio, Crespo, Piero, Herrero, Ana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687808/ https://www.ncbi.nlm.nih.gov/pubmed/36358912 http://dx.doi.org/10.3390/biom12111562 |
Ejemplares similares
-
RAS Dimers: The Novice Couple at the RAS-ERK Pathway Ball
por: Herrero, Ana, et al.
Publicado: (2021) -
Defined spatiotemporal features of RAS-ERK signals dictate cell fate in MCF-7 mammary epithelial cells
por: Herrero, Ana, et al.
Publicado: (2016) -
Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
por: Tubita, Alessandro, et al.
Publicado: (2022) -
Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018) -
Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)